Chugai Pharmaceutical Co., Ltd. 4519

Asian stock markets largely fell back Tuesday as oil prices and bond yields remain firm at relativel

Japanese government bond yields have hit a 30‑year high, putting pressure on risk assets while pushing investors to look harder for growth themes with clear, real world use cases. Healthcare powered by artificial intelligence in Japan sits at the intersection of those needs and opportunities. This article introduces three AI focused healthcare stocks from our screener that investors may wish to evaluate as they consider that shift. The three stocks highlighted below are only a small sample of...

TOKYO, September 09, 2026--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors.

Recently published Autoimmune Uveitis Market Insights report includes a comprehensive understanding of current treatment practices, autoimmune uveitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

With governments such as China channeling fresh fiscal spending into healthcare and social security, artificial intelligence in medicine is moving from theory into real projects that need practical solutions. That creates a window for investors who want exposure to AI tools that may help clinicians, hospitals, and researchers work smarter. This article highlights three Transformative AI Healthcare stocks from our screener that show how this theme is taking shape. The three stocks below are a...

RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, broad geographic reach and expansion into other complement-driven diseases.Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "RG-6299 Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. RG-6299 Market Forecast Highlights Clinical and Commercial Potential Thr

Travere Therapeutics Inc (TVTX) reports record quarterly revenue of $169.6 million, fueled by a 96% surge in FILSPARI sales and successful FSGS launch momentum.

Phylo, Inc. today announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows.

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (NCT06712654). The trial is being conducted at multiple clinical sites in the United States and China and is co-sponsored by Alebund and R1 Therapeutics, Inc. ("R1").

SINGAPORE & SAN FRANCISCO, June 17, 2026--Gero secures $17M in new financing, bringing total funding to $34M to advance AI-driven drug discovery for aging and chronic diseases.

Recently published Immune Thrombocytopenia Market Insights report includes a comprehensive understanding of current treatment practices, immune thrombocytopenia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Major Asian stock markets closed lower Tuesday as new US military strikes on Iran dampened optimism

Asian stock markets largely gained ground Monday on strength in tech issues, and on media reports th

Wondering if Chugai Pharmaceutical's share price still offers value after a strong multi year run? This article unpacks how the current price compares with several valuation checks. The stock last closed at ¥8,585, with a 3.2% decline over the past week and an 8.3% decline over the past month. It is still up 0.8% year to date and 34.6% over 1 year, and very large over 3 and 5 years. Recent coverage has focused on Chugai Pharmaceutical's position within the pharmaceuticals space in Japan and...

Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a “transformational” 2025 during the company’s fourth-quarter and full-year earnings call, pointing to progress advancing its oral biologics delivery platform, the launch of a new clinical study, and a new strategic collab

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.